Paranthaman Modagan, Ganesh K S V Angu Bala, Silambanan Santhi, Venkatapathy Kuzhandai Velu
Department of Biochemistry, Dhanalakshmi Srinivasan Medical College and Hospital, Affiliated to The Tamilnadu Dr MGR Medical University, Perambalur 621 113, Tamil Nadu, India.
Department of Anatomy, Gujarat Adani Insitute of Medical Science, Bhuj, Gujarat 370001, India.
Bioinformation. 2024 Jan 31;20(1):54. doi: 10.6026/973206300200054. eCollection 2024.
Osteoporosis is asymptomatic, in which low bone-mass and micro-architectural deterioration of bone tissue leads to increasing bone fragility and fracture. Vertebral and hip fractures lead to increased mortality, resulting in enormous health care costs. BMD testing by DEXA is used in diagnosis of osteoporosis. However, low-and middle-income populations are unable to conduct periodic examinations of bone mineral status. Thus, current study is mainly aimed at finding a cost-effective diagnostic-marker for osteoporosis. 170 participants, of whom 51 had osteoporosis, 62 had osteopenia and 57 had normal bone-mass. Selection of individuals was based on DEXA scan BMD. Sclerostin was determined by ELISA. The variables were compared using ANOVA test and ROC analysis was performed. Sclerostin levels were significantly decreased in osteoporosis (4.62 ± 1.6 ng/mL) and osteopenia (4.92 ± 1.4 ng/mL) compared with controls (5.74 ± 1.3 ng/mL), (p < 0.0001). Sclerostin level 5.6 ng/mL is the cut-off value for diagnostic purpose, according to good sensitivity and specificity. In patients with osteopenia and osteoporosis, decreased sclerostin levels were associated with an increased disease risk. These relationships were independent of BMD and bone turnover, suggesting that Sclerostin levels may reflect disease-severity in osteoporosis. Sclerostin measurements could become a useful clinical index for diagnosis of osteoporosis.
骨质疏松症是无症状的，骨量低和骨组织微结构恶化会导致骨脆性增加和骨折。椎体和髋部骨折会导致死亡率上升，从而产生巨大的医疗费用。通过双能X线吸收法（DEXA）进行骨密度检测用于骨质疏松症的诊断。然而，低收入和中等收入人群无法定期进行骨矿物质状态检查。因此，当前的研究主要旨在寻找一种具有成本效益的骨质疏松症诊断标志物。170名参与者中，51人患有骨质疏松症，62人患有骨质减少症，57人骨量正常。个体选择基于DEXA扫描的骨密度。通过酶联免疫吸附测定（ELISA）法测定硬化蛋白。使用方差分析（ANOVA）检验比较变量，并进行ROC分析。与对照组（5.74±1.3 ng/mL）相比，骨质疏松症患者（4.62±1.6 ng/mL）和骨质减少症患者（4.92±1.4 ng/mL）的硬化蛋白水平显著降低，（p<0.0001）。根据良好的敏感性和特异性，硬化蛋白水平5.6 ng/mL为诊断目的的临界值。在骨质减少症和骨质疏松症患者中，硬化蛋白水平降低与疾病风险增加相关。这些关系独立于骨密度和骨转换，表明硬化蛋白水平可能反映骨质疏松症的疾病严重程度。硬化蛋白测量可能成为骨质疏松症诊断的有用临床指标。
